SPDL1 and ovarian cancer: High baseline sPD-L1 was also correlated with shorter OS and PFS in ovarian cancer patients receiving surgery or neoadjuvant chemotherapy [23] and with shorter OS in hepatocellular carcinoma patients treated with resection, local ablation, sorafenib or liver transplantation [69].